Background
Gilead develops and sells prescription medicines, including the HIV drug Biktarvy, in domestic and foreign markets. After a Maryland patient received Turkish-market Biktarvy through his employer’s self-funded health plan, Gilead discovered that Rx Valet, Advanced Pharmacy, Affordable RX Meds, and Gregory Santulli had arranged for hundreds of bottles of foreign-market Gilead medicines to be shipped to U.S. patients. Although the imported drugs were authentic and chemically identical to their U.S. counterparts, their foreign-language labels and accompanying materials omitted warnings, identifiers, and other information supplied with the domestic products.
Gilead sued the four direct participants, along with third-party administrator Meritain Health and pharmacy benefit manager ProAct, under the Lanham Act. It alleged that Meritain supplied patient data and processed invoices supporting international sourcing, while ProAct redirected patients to the sourcing program and processed resulting claims. The District of Maryland entered a preliminary injunction barring the defendants from importing, advertising, selling, or facilitating the importation of Gilead-branded medicines from abroad. The defendants brought four consolidated interlocutory appeals.
The Court’s Holding
The Fourth Circuit affirmed. It held that Gilead was likely to prove direct trademark infringement because the imported medicines were not “genuine” for Lanham Act purposes. The court adopted the material-differences doctrine for gray-market goods and applied its low materiality threshold. The foreign products’ different languages, omitted safety warnings and prescribing information, missing National Drug Code numbers, and other labeling differences were material even though the medicines had the same chemical formulation.
The court separately held that the imported medicines bypassed Gilead’s legitimate quality-control system, including temperature monitoring, chain-of-custody documentation, recall procedures, and its closed domestic distribution network. Either the material differences or the departure from those quality controls supported likely consumer confusion, so the first-sale doctrine did not bar Gilead’s claims.
Gilead also was likely to establish contributory infringement against Meritain and ProAct because each continued supplying services to identified direct infringers while knowing or having reason to know of the infringement. Prior specific notice from a trademark owner is not required under the Inwood knowledge standard, and the Fourth Circuit rejected a separate “degree of control” element for service providers. The court also held that the Food, Drug, and Cosmetic Act did not preclude Gilead’s claims, declined to review the denial of Santulli’s personal-jurisdiction motion, and found no abuse of discretion in the district court’s treatment of irreparable harm, the equities, or the public interest.
Key Takeaways
- Foreign-market goods bearing authentic trademarks may still infringe when even slight product, packaging, labeling, or safety-information differences would matter to consumers.
- Goods distributed outside a trademark owner’s legitimate, substantial, and nonpretextual quality controls are not genuine merely because their physical composition is identical.
- In the Fourth Circuit, contributory trademark liability for service providers follows Inwood’s inducement-or-knowledge test; prior notice and a separate showing of control are not required.
Why It Matters
The decision extends established gray-market trademark principles to imported prescription drugs and confirms that labeling, safety information, traceability, temperature monitoring, and recall coverage can be material components of a branded pharmaceutical product. Chemical identity alone does not make a foreign-market drug genuine under the Lanham Act.
The ruling also clarifies the exposure of intermediaries that enable international drug-sourcing programs. Administrators and pharmacy benefit managers may face contributory liability when they knowingly provide patient data, claim processing, referrals, or other services necessary to an identified infringement, even without first receiving a cease-and-desist letter.